Key result
Xinmai'an tablet is the subject of this systematic review and meta-analysis protocol to evaluate its efficacy and safety for premature ventricular contractions due to coronary heart disease, and thus contains no clinical results.
Why the study?
Although clinical studies show Xinmai'an can control premature ventricular contractions in coronary heart disease, no systematic review currently evaluates its effectiveness.
Does Xinmai'an tablet improve premature ventricular contractions in patients with coronary heart disease?
Systematic Review
Does Xinmai'an tablet improve premature ventricular contractions in patients with coronary heart disease?
Answers are grounded in this paper and cite their sources.
This protocol outlines a systematic review and meta-analysis to evaluate the efficacy and safety of Xinmai'an tablet for premature ventricular contractions in patients with coronary heart disease.
BACKGROUND: Coronary heart disease (CHD) is the leading cause of human death in the world and a public health problem of global concern. As a common arrhythmia in CHD, premature ventricular contractions are very likely to progress to fatal arrhythmias, resulting in serious adverse consequences. At present, the treatment of premature ventricular contractions due to CHD mainly focuses on catheter ablation, beta-blockers and antiarrhythmics. Both require ongoing monitoring because relapses may lead to redevelopment of cardiomyopathy, and there are varying degrees of indications and side effects. Several clinical studies have shown that Xinmai'an can effectively control the occurrence of premature ventricular contractions and reduce the risk of recurrence. However, there is currently no systematic review evaluating its effectiveness. Therefore, the purpose of this study is to provide strong evidence-based medical evidence for Xinmai'an tablet in the treatment of premature ventricular contractions due to CHD. METHODS: We will search the main Chinese and English databases from inception to June 5, 2022. And identified as the randomized controlled trials. In addition, a reference list of studies meeting the inclusion criteria will be retrieved. Two researchers will conduct literature screening and quality evaluation. And we will conduct bias risk assessment and sensitivity analysis. The analysis software uses RevMan 5.3. RESULTS: Mainly by observing the number of ventricular premature beat attacks (24-hour holter monitoring electrocardiogram), electrocardiogram efficacy (ST segment and T wave changes) and echocardiogram assesses the structure and function of the left and right ventricular, left ventricular ejection fraction, etc. To evaluate the clinical effect of Xinmai'an on premature ventricular contractions due to CHD. CONCLUSION: The results of this study will provide a basis for the selection of treatment options for premature ventricular contractions due to CHD.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted a systematic review in Premature ventricular contractions due to coronary heart disease. Xinmai'an tablet vs. Conventional treatment of western medicine was evaluated on Number of ventricular premature beat attacks, electrocardiogram efficacy, echocardiogram parameters, and clinical effective rate. Xinmai'an tablet is the subject of this systematic review and meta-analysis protocol to evaluate its efficacy and safety for premature ventricular contractions due to coronary heart disease, and thus contains no clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: